Therapy developer Alumis seeks up to $1 bln valuation in US IPO
Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday.
Alumis eyes $300 million in proceeds in IPO
Biopharmaceutical company Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 a share in its upcoming initial public offering. At the midpoint of its range, Alumis will raise about $300 million with underwriters Morgan Stanley, Leerink Partners, Cantor and Guggenheim Securities.
Alumis' $100 Million IPO: Promising Psoriasis Treatment Results
Alumis Inc. has filed for a $100 million IPO to advance its later-Phase trials treatment programs. Lead candidate ESK-001 shows positive trial results for psoriasis treatment, driving potential demand for company shares. The global psoriasis treatment market forecasted to reach $44 billion by 2031, with Alumis seeking U.S. public capital market investment.
